1. Home
  2. TII vs ALXO Comparison

TII vs ALXO Comparison

Compare TII & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TII

Titan Mining Corporation

N/A

Current Price

$2.31

Market Cap

232.9M

Sector

N/A

ML Signal

N/A

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$1.99

Market Cap

240.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TII
ALXO
Founded
2012
2015
Country
Canada
United States
Employees
167
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
232.9M
240.8M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
TII
ALXO
Price
$2.31
$1.99
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$6.38
$3.50
AVG Volume (30 Days)
264.6K
698.5K
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
26.36
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$4.20
N/A
Revenue Next Year
$3.46
N/A
P/E Ratio
$25.66
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.09
$0.41
52 Week High
$5.65
$2.66

Technical Indicators

Market Signals
Indicator
TII
ALXO
Relative Strength Index (RSI) 37.68 54.37
Support Level $2.09 $1.44
Resistance Level $3.14 $2.27
Average True Range (ATR) 0.20 0.14
MACD -0.02 0.01
Stochastic Oscillator 0.00 52.94

Price Performance

Historical Comparison
TII
ALXO

About TII Titan Mining Corporation

Titan Mining Corp is a Canadian natural resources company. The company is engaged in the acquisition, exploration, development, and extraction of mineral properties. The company owns an interest in the Empire State Mine in Northern New York State, United States, and Kilbourne Graphite Project. The Company operates one reportable segment, mineral production and exploration in the United States.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: